267
Views
6
CrossRef citations to date
0
Altmetric
CAUSATION AND PREVENTION

GPC5 rs2352028 Polymorphism and Risk of Lung Cancer in Han Chinese

, , , , , , & show all
Pages 13-19 | Published online: 31 Jan 2012
 

Abstract

rs2352028 in GPC5 has been reported to be associated with the risk of lung cancer in never-smokers. We performed a replication study in 1,045 lung cancer patients and 1,094 controls of Han Chinese origin. We found no association between rs2352028 and lung cancer/adenocarcinoma in never-smokers, but a p value of .04 (under the recessive model) was obtained between this SNP and overall lung cancer/adenocarcinoma. Our data and a recent meta-analysis suspected the possibility of rs2352028 being a risk variant of lung cancer risk in never-smokers. Our findings suggested that rs2352028 might confer a slight risk to lung cancer/adenocarcinoma.

ACKNOWLEDGMENTS

We warmly thank all the participants for their cooperation in this study and gratefully acknowledge all the physicians and nurses who assisted in studying the patients. This work was supported by 973 Program (2011CB504001, 2010CB529600, 2007CB947300, and 2006CB910601), the 863 Program (2006AA02A407 and 2009AA022701), the Shanghai Municipal Commission of Science and Technology Program (09DJ1400601), the National Key Project for Investigational New Drug (2008ZX09312–003), and the National Natural Science Foundation of China.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.